|Day's Range||56.81 - 58.65|
|52 Week Range||16.61 - 59.50|
|PE Ratio (TTM)||-17.42|
|Earnings Date||Aug 1, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||69.13|
Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful 12-month safety results of the Company’s “Mercury 1” Phase 3 registration trial for its fixed-dose combination product candidate, Roclatan™....
Investors certainly have to be happy with Aerie Pharmaceuticals Inc (AERI) and its short term performance